#WSJHealth

On April 30, 2019, the editors of The Wall Street Journal will again convene influential business leaders, policy makers and experts from across the health and health-care industries to focus on the innovations transforming this critical sector. Featured participants will join a remarkable audience of executives, entrepreneurs and stakeholders from the worlds of science, finance, law and government. There are no prepared speeches. Instead, the Journal’s editors and top journalists will lead dynamic discussions on the most pressing topics, ranging from new technologies, to Washington policy, to evolving private-sector business models.

SPEAKERS

Steve Nelson

Office of the Chief Executive

UnitedHealth Group

CEO, UnitedHealthcare

Steve Nelson is CEO of UnitedHealthcare, a $180 billion division of UnitedHealth Group. UnitedHealthcare serves one in eight Americans, making it the single largest business dedicated to health and well-being in the United States. Previously, Mr. Nelson served as CEO of UnitedHealthcare’s medicare and retirement business, the nation’s largest organization dedicated to seniors and Medicare beneficiaries. Past roles also include leading UnitedHealthcare’s community and state business and leading the West region of UnitedHealthcare’s employer and individual business. Before coming to UnitedHealthcare, he was president of the eastern region and senior products division at HealthNet and served for 10 years in executive roles at the Henry Ford Health System. Mr. Nelson is an avid triathlete and five-time IRONMAN finisher, including the IRONMAN World Championship. He earned a B.A. from Portland State University and holds master’s degrees in business administration and health services administration from the University of Michigan, where he serves as an adjunct professor in the School of Public Health.

Ian C. Read

Chairman and CEO

Pfizer

Ian C. Read leads Pfizer, one of the world’s premier innovative biopharmaceutical companies. Prior to being named chairman of the board in 2011, and CEO in 2010, he served as senior vice president and group president of the worldwide biopharmaceutical businesses, which he led from 2006 through 2010. Mr. Read began his career with Pfizer in 1978. He worked in Latin America through 1995, holding positions including CFO of Pfizer Mexico and country manager of Pfizer Brazil. In 1996, he was appointed president of Pfizer’s international pharmaceuticals group. He became executive vice president, Europe in 2000, was named a corporate vice president in 2001, and assumed responsibility for Canada, in addition to Europe, in 2002. He later also assumed responsibility for operations in the Africa/Middle East region and Latin America. Mr. Read is a director of Kimberly-Clark Corporation. He also serves on the boards of Pharmaceutical Research and Manufacturers of America (PhRMA), International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and the Partnership of New York City. Mr. Read received a B.Sc. in chemical engineering from London University Imperial College and earned a chartered accountants certification from the Institute of Chartered Accountants of England and Wales.

Michael F. Neidorff

Chairman and CEO

Centene Corporation

Michael Neidorff became president and CEO of Centene Corporation in 1996. He was named chairman and CEO in 2004. From the time Mr. Neidorff joined Centene, he has led its transformation from a closely held, $40 million corporation to a publicly traded Fortune 100, diversified, multi-national healthcare enterprise with annual revenues approaching $60 billion. Under Mr. Neidorff’s direction, Centene has expanded from operating Medicaid health plans solely in Wisconsin and Indiana, to operations and implementations in 31 states serving 14.4 million managed care and TRICARE eligible beneficiaries. In 1985, Mr. Neidorff started Physicians Health Plan of Greater St. Louis, a subsidiary of UnitedHealth Group and served as the president and chief executive officer until 1995. From 1995 to 1996, he served as regional vice president of Coventry Health Care, Inc., a publicly traded managed care organization, and as the president and CEO of one of its subsidiaries, Group Health Plan Inc. in St. Louis. He also spent 18 years in international senior executive positions at Miles Laboratories/Bayer AG. Mr. Neidorff graduated from Trinity University and holds an M.A. from St. Francis College.

Belén Garijo

Member of the Executive Board and CEO Healthcare

Merck KGaA, Darmstadt, Germany

Belén Garijo has been a member of the executive board of Merck KGaA, Darmstadt, Germany since 2015 as CEO of the health care business sector. She additionally has executive board responsibility for group human resources and for environment, health, safety, security and quality. Since 2013, she also acts as president and CEO of the biopharma business, where she started in 2011 as COO. Before joining Merck KGaA, Ms. Garijo served as the senior vice president of global operations in Europe at Sanofi-Aventis, where she was a member of the management committee of the Sanofi-Aventis Group and of the management board of the Sanofi-Pasteur vaccines joint venture with MSD. In 2011, she took on the additional role of global integration leader for the Genzyme acquisition. From 2003 to 2006, she was general manager of Aventis Spain, subsequently leading the merger of Sanofi-Aventis in 2004. From 2000 to 2003, she served as global vice president of oncology at Aventis, and from 1996 as director of the oncology business unit in the predecessor company Rhône-Poulenc Rorer. Prior to that, she worked in R&D as medical director of the Abbott Laboratories Spanish affiliate; she later led international medical affairs at Abbott headquarters in the United States. Ms. Garijo is a medical doctor, specialized in clinical pharmacology.

Leonard S. Schleifer, M.D., Ph.D.

Founder, President and CEO

Regeneron

Leonard Schleifer founded Regeneron (NASDAQ: REGN) in 1988, and has been president, CEO and a director since its inception. Mr. Schleifer, together with president and chief scientific officer Dr. George Yancopoulos, has built the company into one of the world’s leading biotechnology companies, with a unique science-driven culture. Regeneron’s ability to consistently translate science into medicine has led to seven FDA-approved treatments and 20 product candidates. The company is accelerating and improving the traditional drug development process through its proprietary VelociSuite technologies, including VelocImmune to yield optimized fully-human antibodies, and ambitious initiatives such as the Regeneron Genetics Center, one of the largest genetics sequencing efforts in the world. Dr. Schleifer has been recognized as one of Barron’s Best CEOs, a Yale School of Medicine Legend in Leadership and an E&Y Life Sciences Entrepreneur of the Year. Under his leadership, Regeneron has been repeatedly voted the number one company to work for in the biopharmaceutical industry by Science magazine and has been consistently ranked a top ten most innovative company by Forbes. Dr. Schleifer graduated from Cornell University and earned his M.D. and a Ph.D. in pharmacology from the University of Virginia. He is a physician certified in neurology by the American Board of Psychiatry and Neurology.

Laurie H. Glimcher, M.D.

President and CEO

Dana-Farber Cancer Institute

Laurie Glimcher is the president and CEO of the Dana-Farber Cancer Institute, principal investigator and director of the Dana-Farber/Harvard Cancer Center and the Richard and Susan Smith professor of Medicine at Harvard Medical School. Previously, she was the Stephen and Suzanne Weiss dean and professor of medicine of Weill Cornell Medicine and provost for medical affairs of Cornell University. From 1991 to 2012, she served as the Irene Heinz Given professor of immunology at the Harvard School of Public Health and professor of medicine at Harvard Medical School serving as senior physician and rheumatologist at Brigham and Woman’s Hospital. Dr. Glimcher is celebrated for her research discoveries in the fields of transcriptional regulation, lymphocyte differentiation, immunology and osteobiology. As an immunologist, her primary research interests are elucidating the molecular pathways that regulate the immune system. Dr. Glimcher is a member of the National Academy of Sciences, a fellow of the American Academy of Arts and Sciences, a member of the National Academy of Medicine and the former president of the American Association of Immunologists. She is the co-founder of Quentis Therapeutics and currently serves on the boards of GlaxoSmithKline Pharmaceutical Corporation and the Waters Corporation. Aside from her research efforts, Dr. Glimcher has been a proponent of improved access to care, health policy and medical education. Dr. Glimcher is a graduate of Radcliffe College and holds an M.D. from Harvard Medical School.

Wright L. Lassiter III

President and CEO

Henry Ford Health System

Wright L. Lassiter III is the president and CEO of Henry Ford Health System, a $6 billion health system comprised of six hospitals, a health plan and a wide range of ambulatory and retail health services consisting of more than 60 clinical locations and 30,000 employees. Mr. Lassiter has more than 25 years of experience working in large, complex health systems, including Methodist Health System in Dallas and JPS Health Network in Fort Worth, Texas. Prior to joining Henry Ford in 2014, he was CEO of Alameda Health System in Oakland, California, where he was credited with leading the expansion and turnaround of the $865 million public health system. Mr. Lassiter’s work has received many national accolades. An avid community leader, Lassiter has held volunteer positions at the United Way, Salvation Army and YMCA. Currently, he serves on the boards of the American Hospital Association, America’s Essential Hospitals, Federal Reserve Bank of Chicago, Detroit Regional Chamber, LeMoyne College, City Year Detroit, and YMCA-USA. Mr. Lassiter received his master’s degree in healthcare administration from Indiana University. He holds a bachelor’s degree in chemistry from LeMoyne College in Syracuse, New York.

James Park

CEO, President and Co-Founder

Fitbit

James Park is Fitbit’s co-founder and has served as chairman since 2015 and as president and CEO since 2007. He was selected to serve as a member of Fitbit’s board of directors in 2007 due to the perspective and experience he brings to those roles. Previously, Mr. Park served as a director of product development at CNET Networks and as the president and a co-founder of Wind-Up Labs, Inc., an online photo-sharing company acquired by CNET Networks in 2005. He was also CTO and a co-founder of Epesi Technologies, Inc., a software company. Mr. Park attended Harvard College, where he studied computer science.

Rachel Haurwitz, Ph.D.

Co-Founder, President and CEO

Caribou Biosciences

Rachel HaurwitHaurwitz z is a co-founder of Caribou Biosciences and has been President and CEO since its inception in 2011. She has a research background in CRISPR-Cas biology, and is also a co-founder of Intellia Therapeutics. In 2014, she was named by Forbes Magazine to the “30 Under 30” list in Science and Healthcare, and in 2016, Fortune Magazine named her to the “40 Under 40” list of the most influential young people in business. In 2018, the Association for Women in Science recognized her with the annual Next Generation Award. Dr. Haurwitz is an inventor on several patents and patent applications covering multiple CRISPR-based technologies, and she has co-authored scientific papers in high impact journals characterizing CRISPR-Cas systems. Dr. Haurwitz earned an A.B. in biological sciences from Harvard College, and received a Ph.D. in molecular and cell biology from the University of California, Berkeley.

Katrine Bosley

CEO

Editas Medicine

Katrine Bosley is the CEO of Editas Medicine (NASDAQ: EDIT). Prior to joining Editas, Ms. Bosley was an entrepreneur-in-residence at The Broad Institute, a biomedical and genomic research center. Before that, she was the CEO of Avila Therapeutics (acquired by Celgene). She was also vice president of business development at Adnexus Therapeutics, where she became vice president of strategic operations after Adnexus’ acquisition by Bristol-Myers Squibb. Earlier, she held several positions at Biogen in business development, commercial operations and portfolio strategy and was part of the health-care team at the venture firm Highland Capital Partners. In addition to her role at Editas, Ms. Bosley currently serves as chairman of the board of Genocea Biosciences (NASDAQ: GNCA) and is a member of the board of directors of Galapagos NV (EURONEXT and NASDAQ: GLPG), BIO – the Biotechnology Innovation Organization, and Massachusetts Eye and Ear. Ms. Bosley is a graduate of Cornell University.

John Arnold

Founder and Co-Chair

Laura and John Arnold Foundation

John Arnold is founder and co-chair of the Laura and John Arnold Foundation (LJAF). LJAF’s core objective is to improve the lives of individuals by strengthening our social, governmental and economic systems. Mr. Arnold is also founder of Centaurus Capital LP, a family office investment fund with a specific focus on the energy industry. Previously, Mr. Arnold founded and was CEO of Centaurus Energy, a multi-billion dollar energy commodity hedge fund. Prior to founding Centaurus Energy, he held positions within Enron’s wholesale division, including head of natural gas derivatives. In 2012, Mr. Arnold announced his retirement from Centaurus Energy to concentrate on philanthropic activities. He serves on the boards of Breakthrough Energy Ventures, an investor-led venture capital firm dedicated to funding transformational technologies that will reduce global greenhouse gas emissions; Civica, Inc., a nonprofit generic pharmaceutical company; and The City Fund, a nonprofit dedicated to supporting new governance models in K-12 education. Mr. Arnold holds a B.A. from Vanderbilt University.

Gina Paige

President and Co-Founder

African Ancestry, Inc.

Gina Paige co-founded African Ancestry, Inc. in 2003. In doing so, she pioneered a new way of tracing African lineages using genetics, and a new marketplace for people of African descent looking to more accurately and reliably trace their roots. With the industry’s largest and most comprehensive database of over 30,000 indigenous African samples, African Ancestry determines specific countries and — more often than not — specific ethnic groups of origin with an unrivaled level of detail, accuracy and confidence. Dr. Paige has worked with and revealed the roots of Oprah Winfrey, John Legend, Spike Lee and Condoleezza Rice, and her work is featured in Finding Your Roots with Henry Louis Gates, Jr., African American Lives 1 & 2, Sirius Satellite Radio, The Africa Channel, NBC’s Who Do You Think You Are? and CNN’s Black in America series. Prior to forming African Ancestry, Paige was the founder and president of GPG Strategic Marketing Resources. Dr. Paige resides in Washington, D.C. She holds a degree in economics from Stanford University and an M.B.A. from the University Of Michigan Ross School Of Business. She also holds an honorary doctorate from Global Oved Dei Seminary University.